Therapy Areas: Cardiovascular
Rare Disease Researcher and Oligonucleotide Chemist Join Stoke Therapeutics Leadership Team
20 April 2018 - - Bedford, Massachusetts-based biotechnology company Stoke Therapeutics, Inc. has expanded its leadership team with the appointments of Gene Liau, Ph.D. and Meena Meena, Ph.D., the com...
Novartis appoints Dr John Tsai as CMO and head of global drug development
19 April 2018 - Novartis (VTX: NOVN) has appointed Dr John Tsai as head of global drug development (GDD) and chief medical officer (CMO), the company announced on Thursday.Joining Novartis on 1 May 20...
Astellas Grants Exclusive License to Cardurion Pharmaceuticals to Develop Clinical Stage Heart Failure Candidate
18 April 2018 - - Cambridge, Massachusetts-based biotechnology company Cardurion Pharmaceuticals has entered an exclusive licensing agreement with Tokyo, Japan-based pharmaceutical company Astellas Ph...
Alnylam Study of Givosiran for Treatment of Acute Hepatic Porphyrias Demonstrates Lowering of Urinary ALA and Decrease in Porphyria Attack Rate
18 April 2018 - - Cambridge, Massachusetts-based RNA interference therapeutics developer Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has presented new results from the Phase 1 and Phase 1/2 open-labe...
Boehringer Ingelheim and Eli Lilly sign academic collaboration with Oxford University
18 April 2018 - Germany-based Boehringer Ingelheim and United States-based Eli Lilly and Company have signed an academic collaboration with the University of Oxford.It was reported yesterday that the ...
Advent International to acquire Zentiva
18 April 2018 - Advent International, a United States-based global private equity company, has entered into discussions to acquire Zentiva, Sanofi's European generics business, it is reported tod...